Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

274
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
274
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

639
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
639
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

415
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
415
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

638
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
638
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

220
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
220

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vericiguat therapy reduces arrhythmic events in heart failure patients with cardiac implantable electronic devices.

Heart rhythm·2026
Same author

Multi-Chamber Reverse Remodeling and Hemodynamic Force Realignment After SGLT2 Inhibitor Initiation in Real-World Heart Failure.

Journal of cardiovascular development and disease·2026
Same author

Gynecologic reconstructive surgery: tailoring the postoperative care to the patient.

Gynecology and pelvic medicine·2026
Same author

Rapid Clinical and Renal Recovery after Transcatheter Tricuspid Valve Replacement.

JACC. Case reports·2026
Same author

Galectin-3 binding protein is upregulated in heart failure with preserved ejection fraction and associated with endothelial nitric oxide synthase deficiency.

GeroScience·2026
Same author

DASH Closure: A Dual Access Strategy for Hemodynamic Closure of Mitral Paravalvular Leaks.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Related Experiment Video

Updated: Jan 4, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.3K

Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist.

Paolo Severino1, Paul J Mather2, Mariateresa Pucci3

  • 1Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy. paolo.severino@uniroma1.it.

Diagnostics (Basel, Switzerland)
|November 6, 2019
PubMed
Summary
This summary is machine-generated.

Advanced heart failure (AdHF) requires advanced interventions like ventricular-assist devices (VADs) when transplants are unavailable. Careful patient selection, considering clinical and psychosocial factors, is crucial for successful AdHF management.

Keywords:
HLM classificationadvanced heart failureend stage heart failureorthotopic heart transplantventricular assist device

More Related Videos

A Modified Technique for Transverse Aortic Constriction in Mice
04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

5.6K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.9K

Related Experiment Videos

Last Updated: Jan 4, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.3K
A Modified Technique for Transverse Aortic Constriction in Mice
04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

5.6K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.9K

Area of Science:

  • Cardiology
  • Medical Interventions

Background:

  • Advanced heart failure (AdHF) presents significant clinical challenges, including worsening symptoms, frequent re-hospitalizations, and high mortality rates.
  • Standard treatments are often insufficient for AdHF, necessitating advanced therapeutic options.

Purpose of the Study:

  • To discuss the role of ventricular-assist devices (VADs) as destination therapy for AdHF patients.
  • To emphasize the critical importance of appropriate patient selection for advanced therapies.

Main Methods:

  • Review of current treatment strategies for AdHF.
  • Discussion of the benefits and selection criteria for VADs.
  • Distinguishing AdHF from end-stage heart failure for appropriate care planning.

Main Results:

  • Ventricular-assist device (VAD) implantation improves prognosis, functional status, and quality of life in AdHF patients, offering survival rates comparable to heart transplantation at one year.
  • Accurate patient selection is paramount for optimizing outcomes and resource allocation.

Conclusions:

  • Ventricular-assist devices (VADs) are a viable option for advanced heart failure (AdHF) patients awaiting transplantation or as destination therapy.
  • Comprehensive patient assessment, including psychosocial factors, is essential for successful VAD therapy and distinguishing candidates from those suited for palliative care.